Prolacta Bioscience

Advancing the Science of Human Milk

Prolacta Bioscience is a research driven company dedicated to advancing the science of human milk.®

As a pioneer in human milk-based nutritional products, Prolacta produces specialty nutritional formulations made exclusively from human milk for critically ill premature infants in the NICU. Prolacta is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MF®., which is then sold to NICUs around the country.

As a for-profit, scientifically driven company we have invested over 40 million dollars in research, clinical studies and facilities to develop and test our human milk derived products. This world class research and development would not have been possible with a non-profit business model.

What is Prolacta’s Human Milk Fortifer, and How Does it Help preemies?
During the last trimester, growing babies receive vast amounts of nutrition through the umbilical cord. However, very premature infants miss this crucial nutrition, and their caloric and protein needs are greater than what breast milk can supply. As a result, the standard practice in the NICU is to fortify breast milk with extra calories and protein to provide enough for the very premature infant’s needs. Until the advent of Prolact+ H2MF, the only way to provide the extra calories and protein was to add cow’s milk-based formula. Prolact+ H2MF, is the only product made from 100% human milk that can supply the extra calories and protein necessary for very premature infants. Prolact+ H2MF is specially designed to be used with mother’s own milk, or donor milk, if the mom’s own milk is unavailable, the combination of which is the best possible nutrition for critically ill premature infants.

In 2007 Prolacta undertook the first ever multicenter randomized clinical study of feeding critically ill premature infants a completely human based, nutritionally adequate diet. The results of this study and a subsequent study, published in 2010 and 2013, demonstrated that a 100% human milk diet, including Prolact + H2MF, improved health outcomes. 1, 2. A third report, combining the data from these two trials, demonstrated additional benefits to a 100% human milk diet that were not seen in either trial individually. 3 Your generous milk donation will be used to produce these life-saving nutritional formulations and help improve the lives of critically ill premature infants. Read more about the studies in the Journal of Pediatrics.

  • Creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in neonatal intensive care units (NICUs).
  • Is setting the new standard of safety and quality in human milk processing and milk collection, with a pharmaceutical grade manufacturing facility that is the first and only of its kind.
  • Developed the first large scale human milk processing facility in the world. Using state-of-the-art formulation, pasteurization and filling processes.
  • Is the only organization that includes a safety combination of DNA matching of mom to milk, testing for drugs and bovine contamination, as well as HIV-1, HCV, and HBV through PCR testing.
  • Is the only organization to provide a human milk fortifier that is made from 100% human milk protein as opposed to cow milk for extremely low birth weight preemies.
  • Is committed to supporting research in the study of human milk and premature infant nutrition in order to make a difference in the lives of the most fragile babies.
  • Is committed to supporting breast feeding and breast feeding initiatives in order to promote 100% breast milk nutrition for premature babies.
  • Is dedicated to recognizing the contribution of breast feeding mothers by making sure the mother never pays any out-of-pocket expenses.
  • Supports Hospitals and National Charities.

Prolacta Bioscience’s mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products.



1.Sullivan S, et al. J Pediatr 2010 DOI: 10.1016/j.jpeds.2009.10.040
2. Cristofalo EA, et al. J Pediatr. 2013;163(1,2,3):1592-1595. doi:10.1016/j.jpeds.2013.07.011
3. Abrams SA, et al. Breastfeeding Medicine (DOI: 10.1089/bfm.2014.0024)